Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Sell

Relative Strength Index

Neutral

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Vincerx Pharma, Inc. Common Stock (VINC)

Pharmaceutical Preparations

https://www.vincerx.com

Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform.

260 SHERIDAN AVENUE, SUITE 400
PALO ALTO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/24/2020

Market Cap

18,723,090

Shares Outstanding

21,380,000

Weighted SO

21,380,570

Total Employees

N/A

Upcoming Earnings

08/05/2024

Beta

1.1560

Last Div

0.0000

Range

0.508-9.372

Chg

0.0073

Avg Vol

181748

Mkt Cap

18723090

Exch

NASDAQ

Country

US

Phone

650 800 6676

DCF Diff

0.1135

DCF

0.4861

Div Yield

0.0000

P/S

14.2489

EV Multiple

-0.4251

P/FV

1.5047

Div Yield %

0.0000

P/E

-0.8043

PEG

-0.0264

Payout

0.0000

Current Ratio

3.4289

Quick Ratio

3.4289

Cash Ratio

1.5013

DSO

282.7778

DIO

0.0000

Op Cycle

282.7778

DPO

535.9847

CCC

-253.2069

Gross Margin

0.2040

Op Margin

-23.3592

Pretax Margin

-21.9954

Net Margin

-21.9954

Eff Tax Rate

-0.0497

ROA

-1.3426

ROE

-2.7665

ROCE

-1.8953

NI/EBT

1.0000

EBT/EBIT

0.9416

EBIT/Rev

-23.3592

Debt Ratio

0.0898

D/E

0.1251

LT Debt/Cap

0.0432

Total Debt/Cap

0.1112

Int Coverage

-40.4934

CF/Debt

-14.6048

Equity Multi

1.3935

Rec Turnover

1.2908

Pay Turnover

0.6810

Inv Turnover

0.0000

FA Turnover

0.7337

Asset Turnover

0.0610

OCF/Share

-0.7364

FCF/Share

-0.7364

Cash/Share

0.4278

OCF/Sales

-21.4848

FCF/OCF

1.0000

CF Coverage

-14.6048

ST Coverage

-22.8406

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

1.5047

P/B

1.5047

P/S

14.2489

P/E

-0.8043

P/FCF

-0.6632

P/OCF

-0.8234

P/CF

-0.8234

PEG

-0.0264

P/S

14.2489

EV Multiple

-0.4251

P/FV

1.5047

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 02, 22:30 $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – VINC, VCSA, MRNS, MHLD GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Jan 07, 15:00 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma GlobeNewswire Inc. Dec 10, 12:00 Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 GlobeNewswire Inc. Dec 10, 12:00 Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 GlobeNewswire Inc. Dec 10, 12:00 Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 GlobeNewswire Inc. Dec 10, 12:00 Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 GlobeNewswire Inc. Dec 10, 12:00 Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 GlobeNewswire Inc. Dec 10, 12:00 Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 GlobeNewswire Inc. Dec 10, 12:00 Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

Revenue Product Segmentation